John Oyler, Chief Executive Officer at BeOne Medicines Ltd. (ONC), sold 145,861 shares at $303.07 ($44.6M) on 2026-07-14, disclosed to the SEC on 2026-07-14.
Scheduled sale ($44.6M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $303.07 | 4,139 | $1.3M | 2.8% |
| 2 | $303.93 | 8,122 | $2.5M | 5.5% |
| 3 | $305.02 | 39,090 | $11.9M | 26.7% |
| 4 | $306.21 | 45,895 | $14.1M | 31.5% |
| 5 | $306.93 | 40,781 | $12.5M | 28.0% |
| 6 | $307.57 | 7,834 |
| $2.4M |
| 5.4% |
| Total | $305.95 avg | 145,861 | $44.6M | 100% |
| Filing → |
| ONC | SELL | 2026-07-17 | $89.4M | — | Filing → |
| ONC | SELL | 2026-07-17 | $20.2M | — | Filing → |
| ONC | SELL | 2026-07-14 | $18.3M | — | Filing → |